DocumentsDate added
Review article
Nagaraj B Malipatil1,*, Kiran M Haridas1, Shruthi D Prithvi2
Affiliation:
1Clinical Pharmacologist, Bangalore, Karnataka, India
2Former Post-graduate, Department of Orthodontics and Dentofacial Orthopedics, DayanandSagar College of Dental Sciences, Bangalore - 560078, Karnataka, India
Address reprint requests to
Dr. Nagaraj B Malipatil.
Clinical Pharmacologist,
Bangalore, Karnataka, India
Article citation:
Malipatil NB, Haridas KM, Shruthi DP. Biosimilars and regulations: A review. J Pharm Biomed Sci. 2015; 05(06):453-468. Available at www.jpbms.info
ABSTRACT:
Currently, all biologics in India, including innovative and bioequivalent biologics (also known as similar biologics in India), are approved as new drugs. Recently in 2012, the Department of Biotechnology (DBT) and Central Drugs Standard Control Organization (CDSCO) issued the “guidelines on similar biologics”. The guidance outlined an abridged procedure for the regulatory requirements for marketing authorization of similar biologics in India.
Due to limited R & D capabilities, most domestic companies manufacture simple biologics. However, companies have increasingly begun to shift their focus to the development of both novel and copy versions of monoclonal antibodies and second-generation biologics, which though more expensive and complex to develop can be priced at a premium, and compete in a much less crowded market than that faced by first-generation biologics.
A number of factors facilitate the development and uptake of Biosimilars in India. Poor patent enforcement in India provides opportunities for domestic biologics manufacturers, while publicprivate sector partnerships promote biologics development. Since there are less stringent regulatory requirements and low R&D costs, domestic biologics are priced much lower in India compared to originators, further driving uptake, as well as offering huge potential for contract manufacturing of biosimilars and for exports. Domestic companies are also entering into partnerships to facilitate development of biologics for the Indian and global market.
However, despite the low price of Biosimilars compared to originator brands, the domestic market is restricted by limited health insurance coverage and therefore poor access to biologic drugs. Also, issues regarding the quality and safety of some domestically manufactured biologics remain a concern among patients and physicians.
KEYWORDS: Biosimilars; Biologics; Regulations; Similar biologic.
REFERENCES:
1.BioSpectrum ABLE Biotech Industry Survey. The eighth survey of Indian biotech industry. 2010. [Accessed on 05 Apr 2015] Available from <http://www.ableindia.org/html/resources/eighth_biospectrum_June_10.pdf.
2.Sheppard A. Modified Biologics: the global outlook Biosimilars, A presentation at Biosimilar Asia Conference 2011, 24-26 May 2011, Grand Hyatt Shanghai, China.
3.Biospectrum- Erythropoietin. 2005. [Accessed on 06 Apr 2015] Available from < http://biospectrumindia.ciol.com/content/BioBusiness/10509062.asp.
4.Business Standard. Angel Broking - Cadila Healthcare - 3QFY2011. 2011. [Accessed on 07 Apr 2015] Available from http://www.business-standard.com/content/research_pdf/cadila_210111_01.pdf.
5.Desai JP. Bridges to Bloom: The Future of Indian Biosimilars” by Universal Consulting India (Pvt) Ltd., September 2009. [Accessed on 08 Apr 2015] Accessed from http://www.universalconsulting.com/pdf/The%20Future%20of%20Indian%20Biosimilars.pdf.
6.CDSCO. Draft guidance on approval of clinical trials and new drugs. 2011. [Accessed on 07 Apr 2015] http://cdsco.nic.in/Guidance_for_New_Drug_Approval-23.07.2011.pdf
7.Shirodkar SN. DBT completes draft guidelines on preclinical trial data for similar biologics. 2011 [Accessed on 08 Apr 2015] Available from http://www.pharmabiz.com/PrintArticle.aspx?aid=63640&sid=1
8.EGA. Global Development, The Way Forward The EGA’s Perspective. 2010a. [Accessed on 08 Apr 2015] Available from: http://www.egagenerics.com/doc/ega_biosimilars_Schwarzenberger_090424.pdf.
9.EGA. 8th EGA Annual International Symposium On Biosimilar Medicines. 2010b. [Accessed on 08 Apr 2015] Available from: http://www.egagenerics.com/bio-articles.htm.
10.Chen H. Requirements For China To Globalize Success Seen In Domestic Biosimilars Market. 2009. [Accessed on 08 Apr 2015] Available from: http://www.genengnews.com/analysis-and-insight/requirements-for-china-toglobalize-success-seen-in-domestic-biosimilars-market/59580243
11.Alexander J. Expert Panel to Recommend Regulatory Guidelines for Biosimilars Soon. 2011. [Accessed on 06 Apr 2015] Available from: http://www.pharmabiz.com/NewsDetails.aspx?aid=60815&sid=1.
12.Dicicco R. Developing Biosimilars in Regulated/Semi-Regulated and Unregulated Markets, A presentation at Informa Life Sciences Biosimilars Conference 2010, June 2010.
13.GaBi. EMA to Revise Overarching Biosimilar Guidelines. 2012. [Accessed on 08 Apr 2015] Available from: http://gabionline.net/Guidelines/EMA-to-revise-overarching-biosimilar-guidelines
14.Kubrekar V. Innovations in drug delivery for biologics to enhance efficacy, A presentation at the Biosimilars India Conference 2011, 14-15 July 2011 Mumbai, India.
15.Tessensohn JA, Yamamoto S. Patent term extensions for biologic innovators in Japan. Nat Biotechnol. 2011; 29(1):34-7.
16.Nomura. Coming of age: generic-centered players flourishing and preparing to go global. 2011 [Accessed on 08 Apr 2015] http://www.nomura.com/europe/resources/upload/Korean_biopharmaceuticals.pdf.
17.Department of Biotechnology. Guidelines on similar biologics. 2012. [Accessed on 08 Apr 2015] Accessed from http://www.igmoris.nic.in/Files2/Guidelines_SimilarBiologics.pdf.
18.Controller General of India. [Accessed on 08 Apr 2015] Available from http://igmoris.nic.in/clinical_trials.asp
19.Clinical Trials Registry – India. Search for trials. 2011. [Accessed on 08 Apr 2015] Available from <http://ctri.nic.in/Clinicaltrials/pubview.php.
20.Department of Industrial Policy & Promotion. Industrial Policy – Industrial licensing. 2011. [Accessed on 08 Apr 2015] Available from <http://dipp.nic.in/inv_opp/manul.pdf.
21.Government of India. Web directory–Union government ministries. 2011. [Accessed on 08 Apr 2015] Available from http://goidirectory.nic.in/union_categories.php?ct=E002.
22.Ministry of Chemicals & Fertilizers. Pharmaceutical policy - 2002. [Accessed on 08 Apr 2015] Available from < http://chemicals.nic.in/pharma4.htm.
23.Ministry of Environment & Forests. Rules for the manufacture, use, import, export and storage of hazardous microorganisms genetically engineered organisms or cells. 1989. [Accessed on 08 Apr 2015] Available from http://envfor.nic.in/legis/hsm/hsm3.html.
24.Parliamentary Standing Committee - 45th report. Issues relating to availability of generic, Generic-branded and branded medicines, their formulation and therapeutic efficacy and effectiveness. 2010. [Accessed on 05 Apr 2015] Available from <http://164.100.47.5/newcommittee/reports/EnglishCommittees/Committee%20on%20Health%20and %20Family%20Welfare/45th%20report.pdf.
25.Ministry of Health and Family Welfare. Drugs and Cosmetics rules 1988 (eighth amendment).1988. [Accessed on 05 Apr 2015] Available from http://dbtbiosafety.nic.in/act/_Annex-7.htm.
26.Tharu R. Clinical Trials in India - Boon or Bane? 2008. [Accessed on 05 Apr 2015] Available from:http://www.medindia.net/news/healthwatch/clinical-trials-in-india-boon-or-bane414191.htm#ixzz3YlVgw7wi.
27.Ariyanchira S. The Opportunity for India in The Global Biosimilars Market. 2010. [Accessed on 05 Apr 2015] Available from: http://www.pharmaphorum.com/2010/06/21/the-opportunity-for-india-in-the-global-biosimilarsmarket/
28.CDSCO. Import or manufacture of a new drug for clinical trials or marketing. 2010. [Accessed on 05 Apr 2015] Available from <http://cdsco.nic.in/html/Sec_122_A.htm
29.Ministry of Health & Family Welfare. Schedule Y - Requirements and guidelines for permission of import and / or manufacture of new drugs for sale or to undertake clinical trials. 2005. [Accessed on 05 Apr 2015] Available from http://dbtbiosafety.nic.in/act/Schedule_Y.pdf
30.Tripathi KK. General approval procedures for biotech medicines - Regulatory approaches and criteria for approvals of biotech medicines in India. 2009. [Accessed on 08 Apr 2015] Accessed from http://www.grips.ac.jp/docs/tripathi.pdf.
31.Ministry of Environment & Forests. Notification regarding adoption of the recommendations of the task force on r-pharma under the chairmanship of Dr. R A Mashelkar, DG-CSIR with effect from 1.4.2006. 2006. [Accessed on 08 Apr 2015] Available from http://envfor.nic.in/divisions/csurv/geac/rpharma_tf.pdf.
32.Subramaniam KV. India as a global leader in biosimilars, A presentation at the Biosimilars India Conference 2011, 14-15 July 2011 Mumbai, India.
33.Arnum PV. Opportunities in the Biosimilars Market. 2010. [Accessed on 05 Apr 2015] Available from:<http://pharmtech.findpharma.com/pharmtech/Ingredients/Opportunities-in-the-BiosimilarsMarket/ArticleStandard/Article/detail/660530>
34.Bourgoin A. What you need to know about the follow-on biologic market in the US: Implications, strategies and impact - competitive landscape. 2011. [Accessed on 05 Apr 2015] Available from <http://thomsonreuters.com/content/science/pdf/ls/newport-biologics.pdf
35.The New Trends of Drug Development Outsourcing in China and India. 2012. [Accessed on 06 Apr 2015] Available from:http://www.researchandmarkets.com/reports/2238850/the_new_trends_of_drug_development_outsourcing_in#pos-0[36 Ghangurde A. Biocon plans biosimilars R&D and production unit in Malaysia. 2010. [Accessed on 05 Apr 2015] Available from http://www.scripintelligence.com/business/Biocon-plans-biosimilars-RandD-and-production-unit-in-Malaysia-305021.
37.Gale J, Bhattacharjee A. Dr. Reddy's is developing eight more drugs. 2007. [Accessed on 06 Apr 2015] Available from http://www.bloomberg.com/apps/news?pid=newsarchive&sid=an605eC_iu.c&refer=home
38.Bhattacharjya AS, Sapra PK. Health Insurance In China And India: Segmented Roles For Public And Private Financing. Health Aff 2008; 27(4):1005-1015.
39.Tandon VR, Mahajan A, Khajuria V, Kapoor V. Biologics and challenges ahead for the physicians. JIACM 2006; 7(4): 334-43.
40.Dey S. 1 insulin price cap for all brands. 2012. [Accessed on 06 Apr 2015] Available from: http://www.business-standard.com/article/companies/1-insulin-price-cap-for-all-brands-112112100017_1.html.
41.WHOSIS. Global Health Observatory. 2010. [Accessed on 08 Apr 2015] Available from: <http://apps.who.int/ghodata/.
42.Joshi SR, Biosimilar peptides: Need for pharmacovigilance. J Assoc Physicians India. 2011 Apr; 59 Suppl: 44-7.
43.Joshi SR. Biosimilar insulins: Are they really 'similar'? 2009. [Accessed on 06 Apr 2015] Available from http://www.japi.org/february_2009/biosimilar_insulins.html.
44.Mody, Goradia, Gupta. How Similar Are Biosimilars In India? 2010. [Accessed on 06 Apr 2015] Available from:http://www.pharmafocusasia.com/research_development/blind-comparative-study.html.
45.Werner R. How biosimilar drugs compare to the original substance - International experts workshop on early treatment strategies for AMI. 2009. Kuala Lumpur. [Accessed on 06 Apr 2015] Available from http://www.metalyse.com/img/download/mi_news_kualalumpur2009.pdf.
46.Yang P. Roche – an innovator’s perspective and position on biosimilars. 2009. [Accessed on 06 Apr 2015] Available from < www.roche.com/irp101005.pdf
47.Patwardhan A. Dr. Reddy’s Position on Biosimilars, A presentation at the FDA Part 15 Public Hearing, November 2010.
48.Kliche W. There Is No Biosimilar ToMetalyse, A presentation at Informa Life Sciences Biosimilars Conference, 2010, June 2010.
49.FDA. Guidance for Industry: Quality Consideration in Demonstrating Biosimilarity to a Reference Protein Product. 2012a. [Accessed on 08 Apr 2015] Available from:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291 134.pdf.
50.FDA. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. 2012b. [Accessed on 08 Apr 2015] Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291 128.pdf.
Source of funding: None
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Copyright © 2015 Malipatil NB, Haridas KM, Shruthi DP. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.